See more : Zhejiang Runtu Co., Ltd. (002440.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Neumora Therapeutics, Inc. Common Stock (NMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neumora Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Sino Agro Food, Inc. (SIAF) Income Statement Analysis – Financial Results
- Tecnotree Oyj (TEM1V.HE) Income Statement Analysis – Financial Results
- Morinaga&Co., Ltd. (MGAAF) Income Statement Analysis – Financial Results
- Ferrotec Holdings Corporation (6890.T) Income Statement Analysis – Financial Results
- FinTech Acquisition Corp. VI (FTVIU) Income Statement Analysis – Financial Results
Neumora Therapeutics, Inc. Common Stock (NMRA)
About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 668.00K | 2.70M | 1.55M | 0.00 |
| Gross Profit | -668.00K | -2.70M | -1.55M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.72M | 104.75M | 212.78M | 87.13M |
| General & Administrative | 45.48M | 31.12M | 24.55M | 8.39M |
| Selling & Marketing | -668.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 44.81M | 31.12M | 24.55M | 8.39M |
| Other Expenses | 0.00 | 405.00K | 11.00K | -3.75M |
| Operating Expenses | 187.53M | 135.87M | 237.32M | 95.52M |
| Cost & Expenses | 188.19M | 135.87M | 237.32M | 95.52M |
| Interest Income | 16.61M | 4.56M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 668.00K | 2.70M | 1.55M | 105.00K |
| EBITDA | -187.53M | -135.28M | -236.79M | -95.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -188.19M | -135.87M | -237.32M | -95.52M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -47.46M | 4.97M | 11.00K | -3.75M |
| Income Before Tax | -235.66M | -130.90M | -237.31M | -99.27M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 268.00K | -4.56M | 301.44K | -101.30K |
| Net Income | -235.93M | -130.90M | -237.31M | -99.27M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -0.86 | -1.56 | -0.65 |
| EPS Diluted | -1.49 | -0.86 | -1.56 | -0.65 |
| Weighted Avg Shares Out | 158.83M | 151.95M | 151.95M | 151.95M |
| Weighted Avg Shares Out (Dil) | 158.83M | 151.95M | 151.95M | 151.95M |
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
Source: https://incomestatements.info
Category: Stock Reports